Nephrology
Outcomes Research in Review
Dapagliflozin Reduces Adverse Renal and Cardiovascular Events in Patients With Chronic Kidney Disease
News
New guidelines address diabetes management in kidney disease
The Kidney Disease: Improving Global Outcomes synopsis document is aimed at primary care physicians and nonnephrology specialists, as well as...
News
New eGFR equation ‘less biased’ by age, kidney function; some disagree
The European Kidney Function Consortium equation surpasses existing equations by "resulting in generally lower bias across the spectrum of age and...
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
FDA/CDC
Terlipressin squeaks by FDA review for hepatorenal syndrome 1
The FDA advisory committee’s 8-7 vote favoring approval of terlipressin for hepatorenal syndrome type 1 reflected concerns and misgivings.
News
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
Author of new article discussing considerations around diabetic ketoacidosis in the setting of COVID-19 also speaks to the findings this week that...
News
Large COVID-19 dataset: Kidney injury in >35% of those in hospital
The clearest risk factors for the development of AKI were “the need for ventilator support or vasopressor drug treatment.”
FDA/CDC
Dapagliflozin trial in CKD halted because of high efficacy
An independent data monitoring committee recommended stopping the trial.